Raviranjan Pandey, Arpan Narayan Roy, Sandip Sarkar, Rakiba Rohman, Kaustav Chakraborty, Rupa Bargakshatriya, Sanjana Pandey, Pruthwiraj, D. Bhattacharya, Saurav Kumar, Saptarshi Maji, Aidan T. Pezacki, Sumit Kumar Pramanik, Christopher J. Chang, Ashima Bhattacharjee, Neelanjana Sengupta, Amitava Das, Arnab Gupta
coordination. In-cellulo studies also revealed that copper-induced vesicularized ATP7B reinstates to Golgi in melatonin-treated hepatocytes. In vivo, melatonin treatment reduced copper-induced oxidative stress in zebrafish embryos and lowered copper burden in Caenorhabditis elegans WD model. Our studies revealed that encapsulation of melatonin within an engineered polymeric nanocapsules having dithiol linkers, susceptible to cleavage by GSH, extended melatonin's circulatory half-life ten-fold and enhanced its ROS-scavenging efficacy three-fold relative to free melatonin. This work introduces a unique dual-function therapeutic strategy that integrates antioxidant activity with copper chelation, simultaneously addressing copper overload and redox imbalance. Repurposing melatonin, with its established clinical safety, offers rapid and cost-effective translational pathway toward WD-therapy while providing a generalizable platform for redox- and metal-associated disorders.